×
About 33,075 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  10,299 results

Population Pharmacokinetic/Pharmacodynamic Joint Modeling of Ixazomib Efficacy and Safe...
https://doi.org/10.1002/psp4.12815
CPT: Pharmacometrics & Systems Pharmacology; Srimani JK, Diderichsen PM et. al.

May 23rd, 2022 - Ixazomib is an oral proteasome inhibitor approved in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM). Approval in the United States, Europe, and additional countries was based on resul...

Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug di...
https://doi.org/10.1016/j.blre.2022.100971
Blood Reviews; Drula R, Iluta S et. al.

May 21st, 2022 - The ubiquitin-proteasome system is the crucial homeostatic mechanism responsible for the degradation and turnover of proteins. As such, alterations at this level are often associated with oncogenic processes, either through accumulation of undegra...

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethason...
https://doi.org/10.1182/bloodadvances.2021006713
Blood Advances; Martin TG, Mikhael J et. al.

May 21st, 2022 - The IKEMA study (NCT03275285) was a randomized, open-label, multicenter phase 3 study investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) vs Kd in patients with relapsed multiple myeloma. In this subanalysis the depth of response ...

Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD...
https://doi.org/10.1002/cam4.4814
Cancer Medicine; Zhang J, Liu Z et. al.

May 21st, 2022 - Tumor-associated macrophages (TAMs) are originated from circulating mononuclear cells in peripheral blood. They result from the recruitment of tumor cells and are a vital constituent of the tumor microenvironment. TAMs may be involved in the immun...

Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DN...
https://doi.org/10.1111/bjh.18230
British Journal of Haematology; Peng F, Wang Y et. al.

May 21st, 2022 - The delivery of bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study, we ev...

see more →

Guidelines  36 results

Management of herpesvirus reactivations in patients with solid tumours and hematologic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810475
Annals of Hematology; Henze L, Buhl C et. al.

Jan 8th, 2022 - Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy ...

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive C...
https://doi.org/10.1016/j.clml.2021.07.028
Clinical Lymphoma, Myeloma & Leukemia; LeBlanc R, Bergstrom DJ et. al.

Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

see more →

Drugs  158 results see all →

Clinicaltrials.gov  811 results

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01998971

May 20th, 2022 - This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, tolerability, and dose of daratumumab when administered in combination with various treatment regimens for different settings of multiple myeloma. ...

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT00339963

May 20th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT02633059

May 20th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated doses (MTD) of idasanutlin and ixazomib (ixazomib citrate) to be used in combination with dexamethasone in patients with relapsed or refractory multiple myeloma with TP53 (17p) deletion. (P...

Tissue Collection for Studies of Lymph Cancer
https://clinicaltrials.gov/ct2/show/NCT01676805

May 20th, 2022 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
https://clinicaltrials.gov/ct2/show/NCT02899052

May 20th, 2022 - A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part ...

see more →

News  1,904 results

43-year-old male • fatigue • unintentional weight loss • pancytopenia • Dx?
https://www.mdedge.com/familymedicine/article/254462/musculoskeletal-disorders
MDedge Family Medicine; Isabella Buzzo Bellon Brout, MD, Caitlin A. Nicholson, MD et. al.

May 10th, 2022 - THE CASE A 43-year-old Black male presented to his primary care physician with an 8-month history of progressive fatigue, weakness, and unintentional weight loss. The patient’s history also included antiphospholipid antibody syndrome (APS) with pr.

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

Cilta-Cel Induces Impressive ORR in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-induces-impressive-orr-in-relapsed-refractory-multiple-myeloma

May 3rd, 2022 - Ciltacabtagene autoleucel (cilta-cel; Carvykti) demonstrated strong overall response rate (ORR) and progression-free survival (PFS) results in patients with relapsed or refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207), according ...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

Frontline Therapy for Multiple Myeloma
https://www.medscape.com/viewarticle/964337

May 3rd, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael, and welcome to Medscape InDiscussion Multiple Myeloma. Today we're talking about frontline therapy for multiple myeloma, and although sometimes w...

see more →

Patient Education  22 results see all →